| abstract |
The invention includes peptidic receptor agonists of the natriuretic system, preferably NPRA and NPRB receptor agonists for the prevention and / or treatment of disease states associated with increased extracellular fluid volume where the second messenger develops cGMP protective properties and which is antihypertrophic (antifibrotic) effect is desired. In particular, the invention includes peptidic receptor agonists of the natriuretic system for the treatment of congestive heart disease, coronary heart disease, organic and functional vascular disorders, nephrotic syndrome, hypertensive disease, myocardial infarction, acute lung injury, erectile dysfunction, primary or secondary fibrosis , liver cirrhosis, pulmonary fibrosis or to improve arterial, venous and capillary blood flow. |